JP2009532434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532434A5 JP2009532434A5 JP2009503576A JP2009503576A JP2009532434A5 JP 2009532434 A5 JP2009532434 A5 JP 2009532434A5 JP 2009503576 A JP2009503576 A JP 2009503576A JP 2009503576 A JP2009503576 A JP 2009503576A JP 2009532434 A5 JP2009532434 A5 JP 2009532434A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- receptor antagonist
- opioid receptor
- naloxone
- icd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims 2
- 239000003401 opiate antagonist Substances 0.000 claims 2
- 206010054196 Affect lability Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000002618 kappa opiate receptor antagonist Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006015733.8 | 2006-04-04 | ||
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| DE102006016991.3 | 2006-04-11 | ||
| PCT/EP2007/053248 WO2007115975A2 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532434A JP2009532434A (ja) | 2009-09-10 |
| JP2009532434A5 true JP2009532434A5 (https=) | 2010-11-11 |
| JP5128578B2 JP5128578B2 (ja) | 2013-01-23 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503576A Expired - Fee Related JP5128578B2 (ja) | 2006-04-04 | 2007-04-03 | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (https=) |
| EP (1) | EP2001456B1 (https=) |
| JP (1) | JP5128578B2 (https=) |
| AT (1) | ATE450256T1 (https=) |
| AU (1) | AU2007236003B2 (https=) |
| CA (1) | CA2646899C (https=) |
| CY (1) | CY1109862T1 (https=) |
| DE (1) | DE502007002185D1 (https=) |
| DK (1) | DK2001456T3 (https=) |
| EA (1) | EA014820B1 (https=) |
| ES (1) | ES2337622T3 (https=) |
| HR (1) | HRP20100113T1 (https=) |
| PL (1) | PL2001456T3 (https=) |
| PT (1) | PT2001456E (https=) |
| RS (1) | RS51211B (https=) |
| SI (1) | SI2001456T1 (https=) |
| WO (1) | WO2007115975A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| ES2694352T3 (es) * | 2013-12-20 | 2018-12-20 | H. Lundbeck A/S | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| LT3137081T (lt) | 2014-04-28 | 2018-02-26 | Orphomed, Inc. | Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| EP1365756A2 (en) * | 2000-08-15 | 2003-12-03 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| JP2004518654A (ja) * | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| CA2521396A1 (en) * | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| CN103087133B (zh) * | 2004-05-26 | 2016-09-14 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
| EP1750675B1 (en) * | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
-
2007
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 HR HR20100113T patent/HRP20100113T1/hr unknown
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de not_active Ceased
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532434A5 (https=) | ||
| JP2009545527A5 (https=) | ||
| JP2006143751A5 (https=) | ||
| JP2011528658A5 (https=) | ||
| JP2011527332A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2007269812A5 (https=) | ||
| JP2010513478A5 (https=) | ||
| JP2013509429A5 (https=) | ||
| JP2012507535A5 (https=) | ||
| JP2009502743A5 (https=) | ||
| JP2012512907A5 (https=) | ||
| JP2012502037A5 (https=) | ||
| JP2012255026A5 (https=) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| JP2010501534A5 (https=) | ||
| JP2005518413A5 (https=) | ||
| JP2013525444A5 (https=) | ||
| JP2006526031A5 (https=) | ||
| JP2009535462A5 (https=) | ||
| JP2011527333A5 (https=) | ||
| JP2010527365A5 (https=) | ||
| JP2008513510A5 (https=) | ||
| CA2530308A1 (en) | 5ht2c receptor agonists for the treatment of diabetes and obesity | |
| JP2012509265A5 (https=) |